

The company presents results from the first 9 months of 2007

### ALMIRALL INCREASES ITS NET SALES BY 3.8%

- **Net sales of over 590 million euros**
- **Normalised net income rose by 17.7%**
- **Latest acquisitions boost Almirall's internationalisation process**

**Barcelona, 14 November 2007.-** Almirall, the international pharmaceutical company located in Spain, achieved net sales of 590.3 million euros in the first 9 months of 2007. This is an increase of 3.8% in comparison to the same period of the previous year. These results reflect positive sales in Spain and at the international level.

Almirall's EBITDA<sup>1</sup> totalled 159.2 million euros in these 9 months, indicating a growth of 21.4% compared to the same period in 2006. This is mainly due to an increase in sales and other income, and lower general, marketing and sales expenses.

These results also reflect Almirall's solid commitment to R&D as a key tool for growth and consolidation in new markets. This is corroborated by its allocation of 78.3 million euros to research and development of medicines, an increase of 27.8% in comparison to its investment of 61.2 million euros for the same period in 2006.

Normalised<sup>2</sup> net income rose by 17.7% during the first 9 months of 2007.

### Almirall Financial Results - Third quarter 2007 (accumulated)

(Figures in millions of euros)

	<b>Third quarter 2007</b>	<b>Third quarter 2006</b>	<b>Increase %</b>
<b>Net sales</b>	590.3	568.6	+3.8
<b>EBITDA</b>	159.2	131.1	+21.4
<b>Net income</b>	125.9	136.7	-7.9
<b>Normalised Net income</b>	125.9	106.9	+17.7

<sup>1</sup> EBITDA (earnings before interest, taxes, depreciations and amortization)

<sup>2</sup> Without including the extraordinary items that concurred in 2006

### Latest acquisitions

From its listing last June, Almirall has announced two acquisitions that show its commitment to reinforcing its internationalisation process, strengthening its presence in countries where it already has its own affiliates (Germany, Belgium, France, Italy, Mexico and Portugal) and establishing its access to new markets.

The company completed the acquisition process of Hermal in August after receiving clearance from the German authorities. The acquisition of this specialised dermatology company with its own R&D team means Almirall complements its therapeutic areas with a range of products for the treatment of skin diseases such as psoriasis, eczema and skin infections.

Almirall recently also communicated the signing of an agreement for the acquisition of a portfolio of 8 products from the pharmaceutical company Shire plc along with part of its sales force. This enables Almirall to increase its range of dermatology drugs as well as reinforcing its portfolio in inflammatory, gastrointestinal and pain areas, creating a base for future operations in the United Kingdom.

**About Almirall**

Almirall, an international pharmaceutical company committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

For further information please visit the website at: [www.almirall.es](http://www.almirall.es)

**For more information:****Ketchum/SEIS**

Sonia San Segundo/ Victoria Hernández

sonia.sansegundo@ketchum.com

Tel.: 91 788 32 00